Cargando…

Dupilumab Treatment is Not Associated with Increased Risk of Overall Skin Infections [Letter]

Detalles Bibliográficos
Autores principales:	Wiggins, Simmi, Levit, Noah A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2023
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10226537/ https://www.ncbi.nlm.nih.gov/pubmed/37256021 http://dx.doi.org/10.2147/ITT.S421440

Ejemplares similares

No Increased Risk of Overall Infection in Adults with Moderate-to-Severe Atopic Dermatitis Treated for up to 4 Years with Dupilumab
por: Blauvelt, Andrew, et al.
Publicado: (2022)

Response to ‘Eruptive keratoacanthomas associated with dupilumab therapy’
por: Patchinsky, Alexandra, et al.
Publicado: (2023)

Dupilumab for the treatment of pembrolizumab‐induced bullous pemphigoid: A case report
por: Pop, Samantha R., et al.
Publicado: (2022)

Reactivation of inflammatory monoarthritis during dupilumab treatment used for prurigo nodularis
por: Bostan, Ecem, et al.
Publicado: (2021)

Severe pemphigoid nodularis successfully treated with dupilumab
por: Jendoubi, Fatma, et al.
Publicado: (2022)

Pilocarpine as a treatment option for dupilumab-related eye manifestations
por: Roh, Won Seok, et al.
Publicado: (2022)

Dupilumab Provides Rapid and Sustained Improvement in SCORing Atopic Dermatitis Outcomes in Paediatric Patients with Atopic Dermatitis
por: WOLLENBERG, Andreas, et al.
Publicado: (2022)

Dupilumab as a novel therapy to treat adrenergic urticaria
por: Goodman, Brian, et al.
Publicado: (2021)

Dupilumab-associated Facial Erythema Successfully Treated With Oral Ivermectin
por: Liane, Javier Gil, et al.
Publicado: (2022)

Dupilumab for the treatment of atopic dermatitis in transplant patients: Two case reports and literature review
por: Napolitano, Maddalena, et al.
Publicado: (2022)

Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis is Efficacious Regardless of Age of Disease Onset: a Post Hoc Analysis of Two Phase 3 Clinical Trials
por: Silverberg, Jonathan I., et al.
Publicado: (2022)

Effectiveness and safety of Dupilumab for the treatment at 104 weeks of recalcitrant bullous pemphigoid
por: Manzo Margiotta, Flavia, et al.
Publicado: (2023)

Effects of dupilumab treatment on patch test reactions: A retrospective evaluation
por: de Wijs, Linde E. M., et al.
Publicado: (2021)

The positive effect of dupilumab on comorbid asthma in patients with atopic dermatitis
por: Spekhorst, Lotte S., et al.
Publicado: (2023)

Eczematous eruption after brodalumab successfully treated with guselkumab and dupilumab
por: Megna, Matteo, et al.
Publicado: (2022)

Reactive perforating collagenosis successfully treated with dupilumab
por: Gil‐Lianes, Javier, et al.
Publicado: (2022)

Dupilumab-associated blepharoconjunctivitis
por: Paulose, Sefy A., et al.
Publicado: (2019)

Dupilumab Treatment Leads to Rapid and Consistent Improvement of Atopic Dermatitis in All Anatomical Regions in Patients Aged 6 Months to 5 Years
por: Siegfried, Elaine C., et al.
Publicado: (2023)

Dupilumab in Inflammatory Skin Diseases: A Systematic Review
por: Olbrich, Henning, et al.
Publicado: (2023)

Skin barrier status during dupilumab treatment in patients with severe atopic dermatitis
por: Ferrucci, Silvia, et al.
Publicado: (2021)

Dupilumab probably reduces transepidermal water loss but does not increase stratum corneum hydration in atopic dermatitis
por: Furuhashi, Takuya, et al.
Publicado: (2020)

Introduction of self-injection increases compliance with dupilumab administration in adult patients with atopic dermatitis: A single-center retrospective study
por: Ito, Makoto, et al.
Publicado: (2020)

Successful treatment of trichothiodystrophy with dupilumab
por: Gruber, R., et al.
Publicado: (2021)

Dupilumab as an adjuvant treatment for keloid-associated symptoms
por: Wong, Audrey Jia Shin, et al.
Publicado: (2021)

Reduced exacerbation frequency and prednisone dose in patients with ABPA and asthma treated with dupilumab
por: van der Veer, Tjeerd, et al.
Publicado: (2021)

Response Letter to the Editor in Reference to Letter to the Editor about “Does Overall Catastrophic Health Care Expenditure Make Sense”?
por: ETEMADI, Manal, et al.
Publicado: (2018)

Dupilumab for the treatment of severe photodermatitis
por: Smith, Mary Patricia, et al.
Publicado: (2019)

Dupilumab-Associated Sezary Syndrome
por: Hamp, Austin, et al.
Publicado: (2023)

Dupilumab therapy following JAK inhibitor withdrawal in moderate–severe atopic dermatitis
por: Kiely, Lisa, et al.
Publicado: (2022)

Changes in Skin and Nasal Microbiome and Staphylococcal Species Following Treatment of Atopic Dermatitis with Dupilumab
por: Olesen, Caroline Meyer, et al.
Publicado: (2021)

Effectiveness of dupilumab for chronic prurigo in elderly patients with atopic dermatitis()
por: Mitsuyama, Shinji, et al.
Publicado: (2023)

Topical treatment of dupilumab-associated refractory conjunctivitis and keratitis
por: Di Staso, Federico, et al.
Publicado: (2022)

A case of Grover disease treated with Dupilumab: Just serendipity or a future perspective?
por: Barei, Francesca, et al.
Publicado: (2022)

Dupilumab‐induced skin‐associated side effects in patients with chronic rhinosinusitis with nasal polyposis
por: Chromy, David, et al.
Publicado: (2022)

Serum IgE reduction and paradoxical eosinophilia associated with allergic conjunctivitis after dupilumab therapy
por: Kimura, Ayaka, et al.
Publicado: (2021)

Letter in response to the case report: “Recalcitrant generalized granuloma annulare treated successfully with dupilumab”
por: Paganini, Claudia, et al.
Publicado: (2023)

Maintenance of response to dupilumab in prurigo nodularis: A retrospective cohort study
por: Selvaraj, Katina J., et al.
Publicado: (2023)

Dupilumab-Associated Mucin Deficiency (DAMD)
por: Barnett, Brad P., et al.
Publicado: (2020)

Dupilumab maintenance therapy in an asthmatic patient with coronavirus disease 2019 pneumonia
por: Tanabe, Naoya, et al.
Publicado: (2021)

Effects of dupilumab in type 1 neurofibromatosis coexisting with severe atopic dermatitis()()
por: Chello, Camilla, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_789ntf784g1cnbiujej9p4dv06